Evidence map›Paper›PMID 42357694›Full record

ArticleViruses2026

Acquired HIV-1 Drug Resistance and Molecular Transmission Networks in Zhongwei, Ningxia, China.

Youping Duan, Subinuer Mutalifu, Ziyang Luo, Yufeng Li, Xiaohong Zhu, Jianxin Pei, Dongzhi Yang, Zhonglan Wu

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Youping DuanCollege of Public Health, Ningxia Medical University, Yinchuan 750004, China.ORCID 0009-0003-1866-8666
Subinuer MutalifuCollege of Public Health, Ningxia Medical University, Yinchuan 750004, China.
Ziyang LuoCollege of Public Health, Ningxia Medical University, Yinchuan 750004, China.
Yufeng LiCollege of Public Health, Ningxia Medical University, Yinchuan 750004, China.ORCID 0009-0004-2223-8631
Xiaohong ZhuCollege of Public Health, Ningxia Medical University, Yinchuan 750004, China.
Jianxin PeiNingxia Center for Disease Control and Prevention, Yinchuan 750011, China.
Dongzhi YangNingxia Center for Disease Control and Prevention, Yinchuan 750011, China.
Zhonglan WuNingxia Center for Disease Control and Prevention, Yinchuan 750011, China.ORCID 0000-0003-3420-1268

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis retrospective cross-sectional study aimed to characterize HIV-1 genotypes, assess drug resistance, and analyze molecular transmission networks in Zhongwei City to inform prevention strategies.

methodsPlasma samples were collected from antiretroviral therapy (ART)-treated patients (2007-2024) with viral load ≥ 200 copies/mL. HIV-1

results75 sequences were obtained. Males (84.00%), and heterosexual transmission (64.00%) predominated. CRF07_BC (46.67%) and CRF01_AE (38.67%) were the major subtypes; the overall ADR rate was 40.00%, mainly NNRTIs-associated (30.67% of all participants, including 16.00% single-class NNRTIs and 14.67% dual-class NRTIs-NNRTIs). Network inclusion rate was 40.00% of the 75 sequences; CRF07_BC showed higher betweenness centrality (

conclusionHIV-1 subtypes are diverse with high ADR. CRF07_BC may act as a transmission bridge, whereas CRF01_AE and CRF85_BC exhibit faster potential spread. Baseline DR testing and network-guided interventions are recommended.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsAdultAnti-HIV AgentsChinaCross-Sectional StudiesFemaleGenotypeHumansMaleMutationPhylogenyRetrospective StudiesViral LoadAnti-HIV Agentsdrug resistancegene subtypeHIV-1molecular transmission network

Identifiers

PMID42357694
PMCPMC13307735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.